Revenue segments as reported by the company.

Pharmaceutical

Animal Health

Other Revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Restructuring costs

Other (income) expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Merck

Merck & Co., Inc. engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Kenilworth, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Merck reports robust Q4 earnings, eyes growth through innovation

Merck's Q4 2022 performance reflects strong revenue growth and strategic advancements across key therapeutic areas, positioning the company for future success.
While facing challenges such as patent estate concerns and competitive pressures, Merck's focus on innovation and partnerships presents opportunities for sustained growth.
Analyst inquiries and executive responses during the earnings call highlight the company's commitment to transparency, patient outcomes, and shareholder value.

Merck reports robust Q1 earnings, eyes growth in oncology and vaccines

Merck's Q1 performance reflects strong revenue growth driven by oncology and vaccines, with a raised full-year guidance and focus on pipeline advancements.
The company's strategic strengths lie in its focus on compelling science, value alignment in business decisions, and commitment to innovation.
Challenges include potential impacts of EU legislation, post-KEYTRUDA LOE growth strategies, and navigating regulatory complexities for new treatments.
Opportunities in expansion in China, revenue diversification, innovative combination therapies, and protective treatment strategies position Merck for future growth.

Merck reports robust Q2 earnings, focuses on growth opportunities

Merck's Q2 performance showcased strong earnings driven by Oncology and Vaccines growth
Despite challenges like regulatory concerns and price pressures, the company remains focused on innovation
Opportunities lie in expanding KEYTRUDA's reach in cancer indications and advancing in immunology
Overall, Merck's strategic acquisitions and commitment to growth position it well for the future

Merck reports robust Q3 earnings, eyes growth in precision medicine

Merck's Q3 2023 Earnings Call highlighted strong revenue growth, pipeline advancements, and increased full-year revenue guidance. The company's strategic focus on key therapeutic areas and precision medicine approaches positions it for continued success and innovation.

Merck reports robust Q4 earnings, eyes growth through strategic investments

Merck's strong Q4 performance was driven by KEYTRUDA and Vaccines, with positive revenue guidance for 2024. The company remains focused on R&D advancements, strategic investments, and shareholder value. Challenges include managing expenses and maximizing market opportunities.

Merck reports robust Q1 earnings, eyes growth in innovative treatments

Merck's Q1 performance reflects strong revenue growth, operational efficiency, and a positive outlook for future earnings.
The company's focus on innovation, strategic investments, and commitment to patient access position it well for long-term success.
Challenges in pipeline differentiation and market competition require continued strategic planning and differentiation strategies.
Opportunities in new treatment areas, market expansion, and upcoming events offer avenues for sustained growth and market leadership.

Merck reports robust Q2 earnings, eyes future drug launches

Merck's Q2 earnings call highlighted strong financial performance, innovative product launches, and confidence in future growth. The company addressed analyst inquiries, emphasizing long-term pipeline growth and short-term financial guidance while expressing gratitude for investor support.

Merck reports solid Q3 earnings, eyes growth through diversification

Merck's Q3 2024 performance reflects revenue growth driven by key products and clinical advancements, despite regional sales variations and inventory challenges.
The company's strengths in diversification, clinical progress, and strategic investments position it well for future growth and competitive edge in the market.
While facing challenges in specific product sales and clinical trials, Merck has opportunities to capitalize on its strengths, expand offerings, and drive sustained growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Merck & Co., Inc. (MRK) CEO Ken Frazier on Q1 2020 Results - Earnings Call Transcript

Merck (MRK) earnings for the pharmaceutical company's first quarter of 2020 have MRK stock falling Tuesday despite beating estimates.
The post Merck Earnings: Why MRK Stock Is 3% Lower Despite Q1 Beats appeared first on InvestorPlace.

Merck Earnings: Why MRK Stock Is 3% Lower Despite Q1 Beats

Pfizer

Merck & Co. Inc. (NYSE: MRK) and Pfizer Inc.

Why Pfizer and Merck Earnings Are Slowing the Dow

The big pharma company delivered strong revenue and earnings growth in Q1. But investors were more concerned about something else.

Why Merck's Q1 Update Disappointed Investors Despite Beating Wall Street Estimates

Merck & Co Inc  said on Tuesday it expects the coronavirus pandemic to reduce 2020 sales by more than $2 billion, and the U.S. drugmaker lowered its profit forecast as a big drop in doctors' office visits during the outbreak will take  a hefty toll, sending its shares down more than 3%.

Merck sees $2.1 billion coronavirus hit to 2020 sales

Merck & Co. (NYSE: MRK) posted stronger than expected profit in the first quarter on Tuesday.

Merck & Co. reports a 10% higher profit in Q1 on solid demand for its cancer drug

Caterpillar

Alphabet

Starbucks

Normally you see a quiet market on the days of a Fed meeting, but today could be an exception because the Fed has done so much already and there’s so many earnings reports out today. Crude remains under pressure but off its worst overnight lows, and volatility continues to ease.

Earnings Buffet: A Plate Of Caterpillar, PepsiCo Now, Alphabet And Advanced Micro Later

Merck (MRK) delivered earnings and revenue surprises of 7.91% and 2.09%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Merck (MRK) Q1 Earnings and Revenues Top Estimates

Merck earnings and sales beat first-quarter estimates, but the Dow Jones drug giant cut 2020 targets due to the coronavirus. Merck stock fell.

Merck Earnings Top, But Pharma Giant Cuts Guidance; Dow Stock Falls

Merck & Co Inc  beat analysts' estimates for quarterly profit on Tuesday on strong demand for its blockbuster cancer drug, Keytruda, but expects coronavirus-led lockdowns to weigh on the treatment's sales in the next few quarters.

Merck profit beats, coronavirus uncertainty weighs on forecast

Bristol-Myers

Johnson & Johnson

Tuesday's big stock charts feature health-care-sector names that may offer value and leadership.
The post 3 Big Stock Charts for Tuesday: Johnson & Johnson, Merck, and Bristol-Myers Squibb appeared first on InvestorPlace.

3 Big Stock Charts for Tuesday: Johnson & Johnson, Merck, and Bristol-Myers Squibb

Merck on Tuesday posted a 10.4% rise in first-quarter profit, helped by strong sales of cancer therapy Keytruda, but the drugmaker lowered its 2020 profit forecast due to uncertainty from the Covid-19 pandemic.

Merck profit rises, cuts 2020 forecast over Covid-19 uncertainty

Shares of Merck & Co. Inc. MRK, +3.13% rose 1% in premarket trading Tuesday, after the drug giant reported first-quarter profit and sales that beat expectations, but provided a downbeat full-year outlook.

Merck's stock gains after profit and sales beat, but outlook is downbeat

What to Watch When Merck and Pfizer Report Tuesday Morning

Dow components Merck and Pfizer have risen into the top 10 in Dow component performance after a volatile first quarter.

Merck and Pfizer Stocks Head Up a Busy Earnings Week

Shares of Merck & Co. Inc. MRK, +0.68% gained 1.9% in premarket trading on Monday after the drugmaker announced a COVID-19 collaboration with the Institute for Systems Biology (IBS), a research organization.

Shares of Merck gain on COVID-19 research collaboration

Apple

Microsoft

Exxon Mobil

Boeing

McDonald's

Visa

Over one-third of the Dow Jones industrial average components are scheduled to report their latest quarterly reports this week.

Apple, Exxon, Microsoft, Pfizer and More Dow Earnings Coming This Week

Merck stock declined 10% from $90 levels in the beginning of this year to $80 levels as of April 22, compared to a 13% decline for the broader S&P 500. While Merck’s stock has marginally outperformed the broader markets, we believe there is over 20% upside potential from the current levels.

Despite Outperforming The Broader Markets, Merck Appears To Be Oversold At $80

Coca-Cola

Mastercard

Wednesday's big stock charts feature names that are preparing to meet with their significant support lines.
The post 3 Big Stock Charts for Wednesday: Coca-Cola, Mastercard, and Merck appeared first on InvestorPlace.

3 Big Stock Charts for Wednesday: Coca-Cola, Mastercard, and Merck

- Ongoing Phase 1 dose escalation and expansion study with CUE-101 as a monotherapy in post first-line recurrent/metastatic HNSCC patients to be amended to include combination of CUE-101 with standard of care KEYTRUDA as first-line therapy  - Preliminary data  from early patient cohorts in the current ongoing CUE-101 monotherapy Phase 1 trial in  post first-line recurrent/metastatic HNSCC patients  demonstrates tolerability and drug exposure, and provides confidence for drug activity consistent with projections based on preclinical data   - Recent publication in Clinical Cancer Research includes supporting preclinical data for CUE-101 demonstrating anti-tumor efficacy as monotherapy and in combination with anti-PD-1 treatment

Cue Biopharma Announces Clinical Trial Collaboration Agreement with Merck to Evaluate CUE-101 in Combination with KEYTRUDA® (pembrolizumab) as First-line Treatment For HPV+ Recurrent/Metastatic Head and Neck Cancer

Merck (MRK) closed the most recent trading day at $82.07, moving -0.93% from the previous trading session.

Merck (MRK) Stock Moves -0.93%: What You Should Know

Merck: What Makes This Big Pharma Tick In April 2020

AbbVie

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials.

Big Pharma Short Sellers Focus on a Couple of Favorites

Merck's (MRK) sBLA seeking approval of Keytruda for advanced solid tumors, based on biomarker, regardless of tumor type, gets FDA's priority review.

News for Merck Stock (MRK)